F11R and cancer: Therefore, we have developed the peptide antagonist to F11R/JAM-A, designated as peptide 4D (P4D), that mimics the trans-homodimerization interface of F11R/JAM-A molecule, thus binding to this active site and blocking the interactions of endothelium with leukocytes and cancer cells [28].